JP2017512759A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512759A5
JP2017512759A5 JP2016554855A JP2016554855A JP2017512759A5 JP 2017512759 A5 JP2017512759 A5 JP 2017512759A5 JP 2016554855 A JP2016554855 A JP 2016554855A JP 2016554855 A JP2016554855 A JP 2016554855A JP 2017512759 A5 JP2017512759 A5 JP 2017512759A5
Authority
JP
Japan
Prior art keywords
seq
cancer
amino acid
homologous
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016554855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512759A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/025305 external-priority patent/WO2015157629A2/en
Publication of JP2017512759A publication Critical patent/JP2017512759A/ja
Publication of JP2017512759A5 publication Critical patent/JP2017512759A5/ja
Pending legal-status Critical Current

Links

JP2016554855A 2014-04-10 2015-04-10 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途 Pending JP2017512759A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461977824P 2014-04-10 2014-04-10
US61/977,824 2014-04-10
US201462057381P 2014-09-30 2014-09-30
US62/057,381 2014-09-30
PCT/US2015/025305 WO2015157629A2 (en) 2014-04-10 2015-04-10 Antibodies, pharmaceutical compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2017512759A JP2017512759A (ja) 2017-05-25
JP2017512759A5 true JP2017512759A5 (https=) 2019-06-27

Family

ID=54288553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554855A Pending JP2017512759A (ja) 2014-04-10 2015-04-10 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途

Country Status (17)

Country Link
US (2) US9902779B2 (https=)
EP (2) EP3662928A1 (https=)
JP (1) JP2017512759A (https=)
KR (1) KR101966408B1 (https=)
CN (2) CN106456727B (https=)
AU (2) AU2015243246B2 (https=)
BR (1) BR112016020009A2 (https=)
CA (2) CA2941029C (https=)
CL (1) CL2016002569A1 (https=)
ES (1) ES2772817T3 (https=)
IL (2) IL246837B (https=)
PH (1) PH12016501976A1 (https=)
RU (1) RU2016138744A (https=)
SG (1) SG11201607258SA (https=)
TW (3) TWI695013B (https=)
WO (1) WO2015157629A2 (https=)
ZA (1) ZA201605175B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015032713B1 (pt) 2013-09-17 2023-03-21 Obi Pharma, Inc Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
JP2017518958A (ja) 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
CA2941029C (en) 2014-04-10 2021-02-16 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
CA3000531A1 (en) * 2015-10-07 2017-04-13 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
GB201612317D0 (en) * 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
CN110072545A (zh) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
TWI822055B (zh) * 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
CN111032083B (zh) * 2017-05-24 2024-01-12 财团法人生物技术开发中心 抗globo h的人源化抗体及其在癌症治疗中的用途
CN119930831A (zh) * 2018-03-14 2025-05-06 纪念斯隆凯特琳癌症中心 抗聚唾液酸抗体及其用途
US20190389963A1 (en) * 2018-06-01 2019-12-26 Obi Pharma, Inc. Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
KR20220016044A (ko) * 2019-03-28 2022-02-08 밍-테인 라이 글로보-h 관련 암 치료법을 위한 동반 진단 검정
US20240066125A1 (en) * 2021-02-09 2024-02-29 Obi Pharma, Inc. Globo series antigens-binding chimeric antigen receptors and uses thereof
WO2026052782A1 (en) 2024-09-06 2026-03-12 Tacalyx Gmbh Anti-globo h antibodies

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
US20040038339A1 (en) 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
EP1293514B1 (en) * 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
AU2003231554A1 (en) * 2002-04-30 2003-11-17 Kyowa Hakko Kogyo Co., Ltd. Antibody to human insulin-like growth factor
ATE483472T1 (de) * 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
DK2270045T3 (en) 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
AU2005259221B2 (en) * 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
US20060287263A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
PL1871805T3 (pl) * 2005-02-07 2020-03-31 Roche Glycart Ag Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
PT2343320T (pt) * 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008087259A1 (en) * 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
AU2009268937A1 (en) 2008-06-16 2010-01-14 Aj Park Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment
MX2010013931A (es) 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
TWI392502B (zh) * 2009-06-16 2013-04-11 Academia Sinica 聚己醣抗原及含新穎醣脂質佐劑之相關抗癌疫苗
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
MX343227B (es) * 2010-04-09 2016-10-28 Aveo Pharmaceuticals Inc Anticuerpos anti-erbb3.
AU2011273351A1 (en) * 2010-07-01 2013-01-17 Dsm Ip Assets B.V. A method for the production of a compound of interest
SG187867A1 (en) * 2010-08-16 2013-03-28 Amgen Inc Antibodies that bind myostatin, compositions and methods
TW201307388A (zh) * 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
EP2497782A1 (en) * 2011-03-08 2012-09-12 Alzinova AB Anti oligomer antibodies and uses thereof
JP6169085B2 (ja) 2011-10-06 2017-07-26 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｅｒｂｂ３抗体に対する腫瘍応答の推定
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2017518958A (ja) * 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
CA2941029C (en) 2014-04-10 2021-02-16 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2017512759A5 (https=)
IL276695A (en) Antibodies, pharmaceutical compositions and uses thereof
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
JP2023002562A5 (https=)
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
JP2021514664A5 (https=)
JP2020528750A5 (https=)
RU2018145852A (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
JP2017149720A5 (https=)
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2015535828A5 (https=)
RU2018124602A (ru) Новые анти-pd-l1 антитела
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
JP2018504105A5 (https=)
JP2016526904A5 (https=)
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
JP2021500916A5 (https=)
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
JP2013542194A5 (https=)
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
JP2015506912A5 (https=)
RU2012103212A (ru) Tlr3 связывающие агенты
RU2016137110A (ru) Антитела к компоненту комплемента с5